Claims
- 1. A pyrazine derivative represented by the following formula: wherein R1 represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom or a protected or unprotected monophosphoric, diphosphoric or triphosphoric acid group; R3, R4, R5 and R6 which may be the same or different represent a hydrogen atom, a halogen atom, an azido group, a substituted or unsubstituted, protected or unprotected hydroxyl or amino group or R4 and R6, taken conjointly, represent a bond; A represents an oxygen atom or a methylene group; n represents 0 or 1; and Y represents an oxygen atom, a sulfur atom or an NH group, or a salt thereof.
- 2. A pyrazine derivative or a salt thereof according to claim 1, wherein R3, R4, R5 and R6 which may be the same or different represent a hydrogen atom, a halogen atom, a substituted or unsubstituted, protected or unprotected hydroxyl group, or R4 and R6 are taken conjointly to represent a bond.
- 3. A pyrazine derivative or a salt thereof according to claim 1, wherein R2 represents a hydrogen atom or a protected or unprotected monophosphoric or triphosphoric acid group.
- 4. A pyrazine derivative or a salt thereof according to claim 1, wherein R2 represents a hydrogen atom or a protected or unprotected monophosphoric acid group; R3, R4, R5 and R6 which may be the same or different represent a hydrogen atom or a protected or unprotected hydroxyl group; A represents an oxygen atom; and n represents 0.
- 5. A pyrazine derivative or a salt thereof according to claim 1, wherein R2 is a hydrogen atom.
- 6. A pyrazine derivative or a salt thereof according to claim 1, wherein Y is an oxygen atom.
- 7. A pharmaceutical composition comprising a compound or a salt thereof according to claim 1 and at least one of a pharmaceutically acceptable carrier or excipient.
- 8. The pyrazine derivative or a salt thereof according to claim 1, selected from the group consisting of4-[(2R,3R,4S,5R)-3, 4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3-oxo-3,4-dihydro-2-pyrazinecarboxamide, 4-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3-oxo-3,4-dihydro-2-pyrazinecarboxamide, 4-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-fluoro-3-oxo-3 ,4-dihydro-2-pyrazinecarboxamide, 6,chloro-4-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3oxo-3,4-dihydro-2-pyrazinecarboxamide, 4-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-3-oxo-3,4-dihydro-2-pyrazinecarboxamide, 4-[(3S,5S,6R)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-3-oxo-3,4-dihydro-2-pyrazinecarboxamide, 4-[(3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-3-oxo-3,4-dihydro-2-pyrazinecarboxamide, {(3aR,4R,6R,6aR)-6-[3-(aminocarbonyl)-2-oxo-1(2H)-pyrazinyl]-2,2-dimethyltetrahydrofuro[3 ,4-d][1,3]dioxol-4-yl}methyl dibenzyl phosphate, {(2R,3S,4R,5R)-5-[3-(aminocarbonyl)-2-oxo-1(2H)-pyrazinyl]-3,4-dihydroxytetrahydro-2-furanyl}methyl dihydrogen phosphate, {(2R,3S,4R,5R)-5-[3-(aminocarbonyl)-2-oxo-1(2H)-pyrazinyl]-3,4-dihydroxytetrahydro-2-furanyl}methyl dibenzyl phosphate, (2R,3R,4R,5R)-4-(acetyloxy)-2-[(acetyloxy)methyl]-5-[3-[amino(imino)methyl]-2-oxo-1(2H)-pyrazinyl]tetrahydro-3-furanyl acetate, 4-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3-oxo-3,4-dihydro-2-pyrazinecarboximidamide hydrochloride, {(2R,3S,4R,5R)-5-[3-(aminocarbonyl)-2-oxo-1(2H)-pyrazinyl]-3,4-dihydroxytetrahydro-2-furanyl}methyl diphosphate, {(2R,3S,4R,5R)-5-[3-(aminocarbonyl)-2-oxo-1(2H)-pyrazinyl]-3,4-dihydroxytetrahydro-2-furanyl}methyl triphosphate, (2R,3R,4R,5R)-4-(acetyloxy)-2-[3-(aminocarbonyl)-5-fluoro-2-oxo-1(2H)-pyrazinyl]-5-(hydroxymethyl)tetrahydro-3-furanyl acetate, (2R,3R,4R,5R)-4-(acetyloxy)-2-[3-(aminocarbonyl)-5-fluoro-2-oxo-1(2H) -pyrazinyl]-5-({[bis(allyloxy)phosphoryl]oxy}methyl)tetrahydro-3-furanyl acetate, {(2R,3S,4R,5R)-5-[3-(aminocarbonyl)-5-fluoro-2-oxo-1(2H)-pyrazinyl]-3,4-dihydroxytetrahydro-2-furanyl}methyl diallyl phosphate, {(2R,3S,4R,5R)-5-[3-(aminocarbonyl)-5-fluoro-2-oxo-1(2H)-pyrazinyl]-3,4-dihydroxytetrahydro-2-furanyl}methyl dihydrogen phosphate n-butylamine, {(2R,3S,4R,5R)-5-[3-(aminocarbonyl)-5-fluoro-2-oxo-1(2H)-pyrazinyl]-3,4-dihydroxytetrahydro-2-furanyl}methyl triphosphate, and 4-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-3-oxo-3,4-dihydro-2-pyrazinecarboxamide.
- 9. The pyrazine derivative or a salt thereof according to claim 1 which is4-[(2R,3R,4S,5R)-3 ,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]3-oxo-3,4-dihydro-2-pyrazinecarboxamide or a salt thereof.
Priority Claims (3)
Number |
Date |
Country |
Kind |
2000-037486 |
Feb 2000 |
JP |
|
2000-040439 |
Feb 2000 |
JP |
|
2000-090071 |
Mar 2000 |
JP |
|
Parent Case Info
This case is a continuation of PCT/JP01/01038 filed on Feb. 14, 2001.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5562859 |
Schlosser et al. |
Oct 1996 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 0010569 |
Feb 2000 |
WO |
Non-Patent Literature Citations (1)
Entry |
J. Davis, et al., “Synthesis and Antiviral Evaluation of Pyrazinones Substituted with Acyclic Chains”, Nucleosides & Nucleotides, 17(5), pp. 875-893 (1998). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/JP01/01038 |
Feb 2001 |
US |
Child |
10/219294 |
|
US |